Histogen Net Worth
Histogen Net Worth Breakdown | HSTO |
Histogen Net Worth Analysis
Histogen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Histogen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Histogen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Histogen's net worth analysis. One common approach is to calculate Histogen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Histogen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Histogen's net worth. This approach calculates the present value of Histogen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Histogen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Histogen's net worth. This involves comparing Histogen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Histogen's net worth relative to its peers.
To determine if Histogen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Histogen's net worth research are outlined below:
Histogen is not yet fully synchronised with the market data | |
Histogen generated a negative expected return over the last 90 days | |
Histogen has high historical volatility and very poor performance | |
Histogen has some characteristics of a very speculative penny stock | |
Histogen has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 19 K. Net Loss for the year was (12.38 M) with loss before overhead, payroll, taxes, and interest of (3.26 M). | |
Histogen currently holds about 12.6 M in cash with (10.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Histogen has a frail financial position based on the latest SEC disclosures |
Histogen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Histogen. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Histogen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
9th of November 2023 Upcoming Quarterly Report | View | |
30th of September 2023 Next Fiscal Quarter End | View | |
30th of June 2023 Last Quarter Report | View |
Follow Histogen's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 85.44 K.Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Histogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Histogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Histogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spada Alfred P over a year ago Acquisition by Spada Alfred P of 313436 shares of Histogen subject to Rule 16b-3 | ||
Satz Brian over a year ago Acquisition by Satz Brian of 6835 shares of Histogen subject to Rule 16b-3 | ||
Spada Alfred P over a year ago Acquisition by Spada Alfred P of 106793 shares of Histogen subject to Rule 16b-3 | ||
Spada Alfred P over a year ago Histogen exotic insider transaction detected |
Histogen Earnings per Share Projection vs Actual
View Histogen Related Equities
Risk & Return | Correlation |
Histogen Corporate Management
Stephen Hill | VP Controller | Profile | |
Steven Mento | Interim Chairman | Profile | |
Thomas Hubka | Director Sec | Profile | |
Gail Naughton | Founder Advisor | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.